Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.9
edited by Sarantis Dimitriadis
on 2022/06/07 08:54
Change comment: There is no comment for this version
To version 2.1
edited by Evdokimos Konstantinidis
on 2021/12/08 12:13
Change comment: There is no comment for this version

Summary

Details

Page properties
Author
... ... @@ -1,1 +1,1 @@
1 -XWiki.Sarantis
1 +XWiki.evdokimosk
Content
... ... @@ -1,324 +322,3 @@
1 -(% class="western" lang="en-GB" style="text-align:justify" %)
2 -(% lang="en-US" %)**End user:** A person who ultimately uses or is intended to ultimately use the product, service or process. In living lab project, end user is defined as a primary study participant who voluntarily participates research after giving informed consent to be the subject of the research.
3 -
4 -(% class="western" lang="en-GB" style="text-align:justify" %)
5 -(% lang="en-US" %)**Living lab research infrastructure end user:** A person or organization who(%%) (% lang="en-US" %)purchases or uses living lab research infrastructure services to conduct a specific contract based research and development activity (often focusing on specifically defined end user group). Living lab research infrastructure end user can also be study participant (a.k.a. end user), if living project is focusing on developing living lab services and infrastructure.
6 -
7 -(% class="western" lang="en-GB" style="text-align:justify" %)
8 -(% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following:
9 -
10 -* (((
11 -(% lang="en-US" %)**Non-professional end users:**
12 -
13 -* (% lang="en-US" %)**Consumers: **Those who buy goods or services for their own use.
14 -
15 -* (% lang="en-US" %)**Public health and social service clients: **Those who use public services.
16 -)))
17 -
18 -* (((
19 -(% lang="en-US" %)**Professional end users**
20 -
21 -* (% lang="en-US" %)**Health professionals and managers:** A person providing health care treatment and advice based on formal training and experience. Also known as healthcare professional or healthcare worker.
22 -
23 -* (% lang="en-US" %)**Social care workers and managers:** Those providing the practical support to help people cope with the day-to-day business of living based on formal training and experience.
24 -
25 -* (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level.
26 -)))
27 -
28 -(% class="western" lang="en-GB" %)
29 -(% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows:
30 -
31 -* (((
32 -(% lang="en-US" %)**Private sector organizations: **(business developers and researchers)
33 -
34 -* (% lang="en-US" %)Tangible equipment and device manufactures
35 -
36 -* (% lang="en-US" %)Health and social service providers
37 -
38 -* (% lang="en-US" %)e-health, IT system and digital technology providers
39 -
40 -* (% lang="en-US" %)Wellbeing and wellness service providers
41 -
42 -* (% lang="en-US" %)Pharmaceutical companies
43 -)))
44 -
45 -* (((
46 -(% lang="en-GB" %)
47 -(% lang="en-US" %)**Public sector organizations:**
48 -
49 -* (% lang="en-US" %)**Local level: **Municipals, cities and other local level public organizations providing e.g. health and social services such as primary health care.
50 -
51 -* (% lang="en-US" %)**Regional level: **e.g.** **Regional** **hospitals providing secondary and tertiary care,** **councils, parliaments, and governments as well as other administrative organizations operating at regional level.
52 -
53 -* (% lang="en-US" %)**National level: **Government agencies, departments or temporary pointed working groups responsible for the specific functions such as health and social services.
54 -
55 -* (% lang="en-US" %)**International level: **European commission departments and agencies as well as other organizations operating at international and transnational level.
56 -
57 -* (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process.
58 -)))
59 -
60 -* (((
61 -(% lang="en-GB" %)
62 -(% lang="en-US" %)**Education and research organizations:**
63 -
64 -* (% lang="en-US" %)**Higher education institutes:** Universities and Universities of Applied Sciences
65 -
66 -* (% lang="en-US" %)**Other educational institutes** covering early childhood, primary, secondary and tertiary education
67 -
68 -* (% lang="en-US" %)**Public research institutions/organizations** such as technical research centers and government laboratories.
69 -
70 -* (% lang="en-US" %)**Private research organizations** such as technology and innovation centers
71 -)))
72 -
73 -* (((
74 -(% lang="en-GB" %)
75 -(% lang="en-US" %)**Civil society organizations:**
76 -
77 -* (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level.
78 -)))
79 -
80 -* (((
81 -(% lang="en-GB" %)
82 -(% lang="en-US" %)**Networks and clusters:**
83 -
84 -* (% lang="en-US" %)Company cluster organizations and company networks
85 -* (% lang="en-US" %)International, national, regional and local networks
86 -)))
87 -
88 -:
89 -
90 -(% class="western" lang="en-GB" %)
91 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table .
92 -
93 -(% style="margin-left:auto; margin-right:auto" %)
94 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)(((
95 -(% class="western" lang="en-GB" style="text-align:center" %)
96 -(% lang="en-US" %)**Age or age group**
97 -)))
98 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
99 -(% lang="en-US" %)Specific age range
100 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
101 -
102 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
103 -(% class="western" %)
104 -
105 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
106 -(% class="western" %)
107 -
108 -)))
109 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
110 -(% class="western" lang="en-GB" %)
111 -(% lang="en-US" %)Elderly
112 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
113 -(% class="western" lang="en-GB" %)
114 -(% lang="en-US" %)Adults
115 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
116 -(% class="western" lang="en-GB" %)
117 -(% lang="en-US" %)Youth
118 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
119 -(% class="western" lang="en-GB" %)
120 -(% lang="en-US" %)Children
121 -)))
122 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
123 -(% class="western" %)
124 -
125 -)))
126 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
127 -(% class="western" lang="en-GB" style="text-align:center" %)
128 -(% lang="en-US" %)**Health status**
129 -)))
130 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
131 -(% class="western" lang="en-GB" %)
132 -(% lang="en-US" %)Healthy
133 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
134 -(% class="western" lang="en-GB" %)
135 -(% lang="en-US" %)Patient
136 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
137 -(% class="western" lang="en-GB" %)
138 -(% lang="en-US" %)Rehabilitant
139 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
140 -(% class="western" lang="en-GB" %)
141 -(% lang="en-US" %)Recovered/Survivor
142 -)))
143 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
144 -(% class="western" %)
145 -
146 -)))
147 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
148 -(% class="western" lang="en-GB" style="text-align:center" %)
149 -(% lang="en-US" %)**A specific disease, disorder or disability**
150 -)))
151 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
152 -(% class="western" lang="en-GB" %)
153 -(% lang="en-US" %)ADHD
154 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
155 -(% class="western" lang="en-GB" %)
156 -(% lang="en-US" %)Dementia
157 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
158 -(% class="western" lang="en-GB" %)
159 -(% lang="en-US" %)Parkinsons’ disease
160 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
161 -(% class="western" lang="en-GB" %)
162 -(% lang="en-US" %)Loneliness and Social Isolation
163 -)))
164 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
165 -(% class="western" lang="en-GB" %)
166 -(% lang="en-US" %)Autism
167 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
168 -(% class="western" lang="en-GB" %)
169 -(% lang="en-US" %)Down syndrome
170 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
171 -(% class="western" lang="en-GB" %)
172 -(% lang="en-US" %)Physical disability
173 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
174 -(% class="western" lang="en-GB" %)
175 -(% lang="en-US" %)Mental health
176 -)))
177 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
178 -(% class="western" lang="en-GB" %)
179 -(% lang="en-US" %)Cardiovascular disease
180 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
181 -(% class="western" lang="en-GB" %)
182 -(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF)
183 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
184 -(% class="western" lang="en-GB" %)
185 -(% lang="en-US" %)Sleep apnea/apnea
186 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
187 -(% class="western" lang="en-GB" %)
188 -(% lang="en-US" %)Mild cognitive impairment
189 -)))
190 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
191 -(% class="western" lang="en-GB" %)
192 -(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD)
193 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
194 -(% class="western" lang="en-GB" %)
195 -(% lang="en-US" %)Language disability
196 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
197 -(% class="western" lang="en-GB" %)
198 -(% lang="en-US" %)Substance abuse (drugs, alcohol)
199 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
200 -(% class="western" lang="en-GB" %)
201 -(% lang="en-US" %)Multiple sclerosis
202 -)))
203 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
204 -(% class="western" lang="en-GB" %)
205 -(% lang="en-US" %)Cognitive disorder (mild, major)
206 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
207 -(% class="western" lang="en-GB" %)
208 -(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation
209 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
210 -(% class="western" lang="en-GB" %)
211 -(% lang="en-US" %)Trauma patient
212 -
213 -(% class="western" lang="en-GB" %)
214 -(% lang="en-US" %)(e.g., a spinal cord injury)
215 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
216 -(% class="western" lang="en-GB" %)
217 -(% lang="en-US" %)Neurodegenerative diseases
218 -)))
219 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
220 -(% class="western" %)
221 -
222 -)))
223 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
224 -(% class="western" lang="en-GB" style="text-align:center" %)
225 -(% lang="en-US" %)**Clients of a specific service**
226 -)))
227 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
228 -(% class="western" lang="en-GB" %)
229 -(% lang="en-US" %)Child welfare
230 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
231 -(% class="western" lang="en-GB" %)
232 -(% lang="en-US" %)Nursing home
233 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
234 -(% class="western" lang="en-GB" %)
235 -(% lang="en-US" %)Employment service
236 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
237 -(% class="western" %)
238 -
239 -)))
240 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
241 -(% class="western" lang="en-GB" %)
242 -(% lang="en-US" %)Early childhood education
243 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
244 -(% class="western" lang="en-GB" %)
245 -(% lang="en-US" %)Home care
246 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
247 -(% class="western" lang="en-GB" %)
248 -
249 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
250 -(% class="western" lang="en-GB" %)
251 -
252 -)))
253 -|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
254 -(% class="western" %)
255 -
256 -)))
257 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
258 -(% class="western" lang="en-GB" style="text-align:center" %)
259 -(% lang="en-US" %)**Vulnerable groups**
260 -)))
261 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
262 -(% class="western" lang="en-GB" %)
263 -(% lang="en-US" %)Minors/Children
264 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
265 -(% class="western" lang="en-GB" %)
266 -(% lang="en-US" %)Single parents with minor children
267 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
268 -(% class="western" lang="en-GB" %)
269 -(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence
270 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
271 -(% class="western" lang="en-GB" %)
272 -(% lang="en-US" %)Substance users
273 -
274 -(% class="western" lang="en-GB" %)
275 -(% lang="en-US" %)(drugs, alcohol)
276 -)))
277 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
278 -(% class="western" lang="en-GB" %)
279 -(% lang="en-US" %)Disabled people
280 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
281 -(% class="western" lang="en-GB" %)
282 -(% lang="en-US" %)Victims of trafficking in human beings
283 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
284 -(% class="western" lang="en-GB" %)
285 -(% lang="en-US" %)Ethnic minorities and immigrants
286 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
287 -(% class="western" lang="en-GB" %)
288 -(% lang="en-US" %)Isolated people
289 -)))
290 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
291 -(% class="western" lang="en-GB" %)
292 -(% lang="en-US" %)Elderly people
293 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
294 -(% class="western" lang="en-GB" %)
295 -(% lang="en-US" %)Persons with serious illnesses
296 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
297 -(% class="western" lang="en-GB" %)
298 -(% lang="en-US" %)Homeless people
299 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
300 -(% class="western" lang="en-GB" %)
301 -(% lang="en-US" %)Ex-prisoners and people with criminal background
302 -)))
303 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; text-align:left; vertical-align:middle; width:153px" %)(((
304 -(% class="western" lang="en-GB" %)
305 -(% lang="en-US" %)Pregnant women
306 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
307 -(% class="western" lang="en-GB" %)
308 -(% lang="en-US" %)Persons with mental disorders
309 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
310 -(% class="western" lang="en-GB" %)
311 -
312 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
313 -(% class="western" lang="en-GB" %)
314 -
315 -)))
316 -
317 -:
318 -
319 -(% class="western" lang="en-GB" %)
320 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .
321 -
322 322  |**Researcher expertise**|**Brief use case description**
323 323  |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making
324 324  |Experts in communication studies|Defining written, oral, visual and digital communication within a certain workplace. Evaluating (multi professional) healthcare team collaboration, communication and debriefing in various healthcare situations in simulated environments (especially in Simulation lab)
... ... @@ -340,4 +340,4 @@
340 340  |Neuroscientists|Focusing on the brain and its impact on behaviour and cognitive functions (cognitive neuroscience, EEG-based BMI research, protocol / paradigm testing, study framework evaluation)
341 341  |Innovation and design management researchers|Ecosystem and innovation management research, social network analysis. Evaluating how health and wellbeing ecosystem operates between different actors at local, regional, national and international level, including also scaling and commercialization
342 342  |Experts in organizational studies|Co-creation, experimentation, organizational research, experts by experience / pier support included. Evaluation how multistakeholder collaboration and co-creation is done and how effective it is. Evaluates experimentations and experimentation culture. How users are involved into these processes
343 -|Data Scientists|Collecting, analysing and interpreting digital data, such as data analytics in healthcare and digital patient recordings (how patient information recording process is managed and utilized during the intervention by using digital tools in simulated situations)
22 +|~{~{id name="AnchorName" /}}Data Scientists|Collecting, analysing and interpreting digital data, such as data analytics in healthcare and digital patient recordings (how patient information recording process is managed and utilized during the intervention by using digital tools in simulated situations)
XWiki.XWikiComments[0]
Comment
... ... @@ -1,5 +1,0 @@
1 -I think in general, the title 'Customer segments' is confusing. When I think customers of living lab methodologies, I think about businesses, healthcare organizations, public authorities, universities... and not about the researchers.
2 -
3 -Shouldn't the title rather be 'Research fields for H&W Living Labs'?
4 -
5 -Also, for the same reason, I do not understand the link with the title 'Living Lab Business model'. Not the researchers but the actual users of the living lab activities (cf. above) are crucial in the business model, as they (should) pay for the living lab services and gain interest and insights from them)
Date
... ... @@ -1,1 +1,0 @@
1 -2022-01-10 15:43:06.877
Selection
... ... @@ -1,1 +1,0 @@
1 -Researcher expertise
State
... ... @@ -1,1 +1,0 @@
1 -SAFE
Target
... ... @@ -1,1 +1,0 @@
1 -Living Lab Business Model.Customer segments in Health and Wellbeing Living Labs.WebHome

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101007990

Copyright © 2021 VITALISE Project